Iambic, an AI drug discovery specialist, banks $150M in an IPO
Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.